Dr Khurum Khan

University College London Hospitals

Dr Khurum Khan is a research-active consultant who trained in medical oncology at the Northern Ireland Cancer Centre and Royal Marsden NHS Foundation Trust London. He studied mechanisms of response and resistance to targeted therapies in advanced colorectal cancer and gained MD(Res) degree under supervision of Professor David Cunningham at the Institute of Cancer Research and the Royal Marsden Hospital. He was involved in setup and conduct of large multicentre academic and translational studies from the time that he spent in full-time research, which included working as trial physician for phase II/III studies in early and advanced gastrointestinal cancers.

In collaboration with Professor Cunningham, Dr Khan secured funding from industry to run an academic phase II study of a multikinase inhibitor in metastatic refractory colorectal cancer. He also wrote a successful application for NIHR portfolio adoption of this study.

Dr Khan is a consultant in Gastrointestinal Oncology at UCLH and attends NMUH. He is also the Clinical Lead of Carcinoma of Unknown Primary (CUP) at NMUH. He is actively involved in translational research and has presented and lectured in international conferences and public forums respectively. Dr Khan published several high impact papers in peer-reviewed journals including Science, Cancer Discovery, Gut, Gastroenterologist, Clinical Cancer Research, Oncogene, Oncologist, BMC Cancer, and British Journal of Cancer. He served as expert member of National Research and Ethics Committee.

Dr Khan has also played an active role in improving the educational experience of the junior doctors nationally. He writes questions for MRCP(UK) and Medical Oncology exams, and remains part of the national medical oncology recruitment panel.

dont miss

Translational research in GI Oncology- how to make progress?

Personalized medicine has made serious inroads in management of cancer patients across different cancer types; however, the progress in GI malignancies has rather reached a plateau in last decade or so. This talk will highlight how to design clinical trials in a cost-effective but scientifically meaningful way such that clinical outcomes can be optimized.

EVEN MORE SEMINARS

  • Dr Penny Kechagioglou: Speaking at the Oncology Convention

    Dr Penny Kechagioglou
    GenesisCare UK

    Breast cancer Service of the Future: a service transformation

  • Mr Hamish Clouston: Speaking at the Oncology Convention

    Mr Hamish Clouston
    The Christie NHS Foundation Trust

    Surgical Management of Advanced Colonic and Rectal Malignancies.

  • Professor David Snead: Speaking at the Oncology Convention

    Professor David Snead
    University Hospitals of Coventry and Warwickshire NHS Trust

    Digital Pathology – the scope and potential return on investment.

  • Anders Johnsson: Speaking at the Oncology Convention

    Anders Johnsson
    Scandinavian ChemoTech AB

    Dynamic-ElectroEnhanced Chemotherapy brings relief to palliative patients with a large tumour burden

  • Islam Elkonaissi: Speaking at the Oncology Convention

    Islam Elkonaissi
    The Royal Marsden NHS Foundation Trust

    The Multi-Specialty Challenge of Cancer Care